Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

STREAM trial: Enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk PSA recurrent PC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.02.19
Views: 652
Rating:

Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA

Prof Andrew Armstrong speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about the STREAM trial investigating the use of enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in patients with high-risk PSA recurrent prostate cancer.

He explains that the trial studied nearly 40 men over a course of 6 months with enzalutamide and ADT with salvage radiation showing that 65% of men were free of disease and off therapy after 3 years.

Prof Armstrong states that the 2/3 year outcomes are superior to what would normally be expected suggesting that enzalutamide could be more effective in improving long term remission rates in these patients.

Related videos

follow us

Tobacco Dependence e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation